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Objective: The mechanism behind the epidemiologically evident inverse relation between Helicobacter pylori 
seropositivity and risk of oesophageal adenocarcinoma (OAC) remains obscure. Severe corpus gastritis is 
unlikely to be in the causal pathway. With the hypothesis of a uniformly low risk, the associations of OAC with 
See end of article for duodenal ulcer and gastric ulcer were explored, both linked to H pylori infection but with different patterns of 
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(OSCC) with these ulcer types were also addressed. 
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1.7, 95% CI 1.1 to 2.5). Gastric ulcer was unrelated to OAC (SIR 1.1, 95% CI 0.6 to 1.7). Although duodenal 
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O
esophageal cancer ranks as the tenth most common 
cancer in the world.1 Several epidemiological studies 
have provided evidence of a dramatic increase in the 
incidence of oesophageal adenocarcinoma (OAC) in Western 
countries,2–6 whereas a slight decrease has been noted for 
oesophageal squamous cell carcinoma (OSCC) in some 
reports2 3  although not in all.4 5  Additionally, the rates of these 
two histological types of oesophageal cancer show marked 
geographical variations.1 
There is strong epidemiological evidence that Helicobacter 
pylori infection, especially with strains carrying the cytotoxin­
associated gene A (CagA), is associated with a reduced risk of 
OAC.7–12 13 In fact, based on an intriguing secular concurrence of 
the rise in oesophageal adenocarcinoma incidence and an 
obvious decrease in H pylori infection prevalence (and a 
decrease in diseases related to H pylori such as duodenal ulcer 
and gastric ulcer), it has been proposed that these two trends 
are causally related.14 On the other hand, a past history of 
infection with CagA+ H pylori was associated with a more than 
twofold increased risk of OSCC in our Swedish population-
based case-control study.10 
The mechanism by which infection with H pylori infection 
might be reducing the risk of oesophageal adenocarcinoma 
remains obscure. Some studies suggest that H pylori infection, 
by its ability to induce gastric atrophy and hypochlorhydria, 
may confer protection against severe reflux, a strong risk factor 
for oesophageal adenocarcinoma.15 16 The inverse association 
between H pylori infection and risk of OAC, however, was 
seemingly independent of presence or absence of significant 
gastric atrophy,10 and pernicious anaemia—accompanied by 
severe corpus atrophy—is not linked to a reduced OAC risk.17 
Moreover, some reports showed improvement of reflux 
oesophagitis after eradication of H pylori in patients with 
duodenal ulcer.18 19 H pylori designated as a class I gastric 
carcinogen by International Agency for Research on Cancer 
(IARC),20 has a central role in peptic ulcer disease aetiology.21 22 
Ninety per cent of patients with duodenal ulcer and 70–90% of 
those with gastric ulcer harbour H pylori in their stomachs.23 
Duodenal ulcer is associated with antral colonisation and 
hyperchlorhydria, whereas gastric ulcer is linked to infection of 
the gastric corpus resulting in a tendency towards hypochlor­
hydria. 
Few studies have explored the risk of oesophageal cancer by 
histology in patients with peptic ulcer. Duodenal ulcer and 
gastric ulcer could be seen as two informative models of H pylori 
infection with important differences in site of infection and 
consequences for gastric acid secretion. 
We thus conducted a large retrospective cohort study to 
investigate the risk of oesophageal cancer by histology among 
patients hospitalised for gastric ulcer or duodenal ulcer from 
1965 to 2003 in Sweden. 
MATERIAL AND METHODS 
The study population 
Data on individual hospitalisations have been collected in the 
Swedish Inpatient Register by the National Board of Health and 
Welfare since 1964. Each record contains the National 
Registration Number (NRN)—an individually unique personal 
identifier assigned to every Swedish resident from birth or 
immigration—as well as medical data, including diagnoses at 
discharge (coded according to the International Classification of 
Abbreviations: CagA, cytotoxin-associated gene A; CI, confidence 
interval; H pylori, Helicobacter pylori; NRN, national registration number; 
OAC, oesophageal adenocarcinoma; OSCC, oesophageal squamous cell 
carcinoma; SIR, standardised incidence ratio 
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Diseases, 7th revision (ICD-7)24 to 1968, 8th revision (ICD-8) 
from 1969 to 1986, 9th revision from 1987 to 1996 and 10th 
revision thereafter) and surgical procedures (coded according to 
the Swedish Classification of Operations and Major Procedures 
to 1996 and the Nordic Medico-Statistical Committee classifi­
cation of surgical procedures thereafter). 
The cohort(s) 
All patients in the Inpatient Register who survived to be 
discharged between 1965 and 2003 with a diagnosis of 
duodenal ulcer (ICD-7 code 541, ICD-8 and ICD-9 code 532, 
and ICD-10 code K26) or gastric ulcer (ICD-7 code 540, ICD-8 
and ICD-9 code 531, and ICD-10 code K25) were considered for 
inclusion in the cohorts. We did not include individuals with 
records of both gastric ulcer and duodenal ulcer. For each 
potential subject, we identified the first recorded hospitalisa­
tion for the ulcer as the index episode. 
The NRNs were first checked in the nationwide registers of 
total population, emigration and causes of death. NRNs that 
could not be located in any of these registers were regarded as 
invalid, and for this reason 4731 corresponding records were 
excluded. We further excluded 22 946 patients with a diagnosis 
of any cancer before or at time of the index episode, 12 323 
individuals who died during the index hospitalisation and 1912 
records because of other inconsistencies. Finally, our cohorts 
encompassed 181 053 individuals. 
Follow-up 
We linked the NRNs to the nationwide and essentially complete 
registers of migration and causes of death to obtain censoring 
information. The national Swedish Cancer Register, established 
in 1958 and more than 98% complete,25 was used to identify 
incident cancer cases in the cohort. We only considered first 
cancers and excluded all benign tumours and cancers found 
incidentally at autopsy. The Cancer Register used ICD-7 as the 
coding scheme through the entire study period, and a World 
Health Organization pathology code was used to record 
histological types of cancer where applicable. We used ICD-7 
code 150 for oesophageal cancer, whereas the pathology code 
146 and 096 denoted OSCC and OAC, respectively. The patients 
in the cohort were followed from the date of discharge from 
their first recorded in-hospital episode with duodenal ulcer or 
gastric ulcer until the date of a diagnosis of any cancer, 
emigration, death, partial/total gastrectomy, vagotomy, or until 
31 December 2003, whichever occurred first. 
Selection bias may result if prodromal symptoms from yet 
undetected preclinical oesophageal cancers increase the prob­
ability of being hospitalised with a peptic ulcer diagnosis. 
Therefore, we excluded the first year of follow-up from our 
analysis to eliminate such selection bias. On the other hand, 
because most hospitalised patients with peptic ulcer will 
undergo an upper endoscopy, it is expected that the population 
is newly screened at time of entry, and that the incidence of 
oesophageal cancer will be artificially decreased during the first 
years of follow-up. 
Statistical analysis 
The standardised incidence ratio (SIR)—the ratio of the 
observed to the expected number of cancers—was used as a 
measure of relative risk of oesophageal cancer among patients 
with duodenal and gastric ulcer. The expected number of 
cancers was calculated on the basis of the person–time 
experienced by the cohorts, divided into strata of sex, age (in 
five-year groups) and calendar year of observation (in five-year 
intervals). The stratum-specific numbers of accumulated 
person–years were multiplied by the cancer incidence rates in 
the corresponding strata, observed in the entire Swedish 
population. These incidence rates were computed by using the 
number of midyear population without a previously reported 
cancer as the denominator. The 95% CIs for the SIRs were 
calculated assuming that the observed events followed a 
Poisson distribution.26 We performed stratified analyses by 
follow-up duration, sex, presence of complications (bleeding or 
perforation) at index of hospitalisation, calendar period of 
index hospitalisation (before versus after 1980), age at entry 
(less than 50, 50–69, 70–) and the calendar period of follow-up 
(before versus after 1995). Comparisons of relative risks among 
strata were done with Poisson regression. 
All statistical analyses were performed with SAS, release 8.2 
(SAS Institute, Cary, North Carolina, USA). Proc Genmod was 
used for Poisson regression and the logarithm of the expected 
number of cases was used as offset variable. All statistical tests 
were two-sided. 
RESULTS 
The final cohort included 61 548 unoperated patients with 
duodenal ulcers (64.5% male) and 81 379 unoperated patients 
with gastric ulcers (52.6% male). Table 1 presents character­
istics of patients in the cohorts. The reason for hospitalisation 
was bleeding for 49% and perforation for 9% of the patients 
with duodenal ulcer, whereas the corresponding percentages 
were 47% and 9% for those with gastric ulcer. 
Duodenal ulcer 
Among the 61 548 unoperated patients with duodenal ulcer 
followed for an average of 9.1 years, OAC occurred in 27 
patients after the first year of follow-up (SIR 1.7; 95% CI 1.1 to 
2.5; table 2). Upon stratification, the SIR tended to be slightly 
higher, and statistically significant, only during years 2–10 of 
follow-up, but the point estimate, although based on small 
numbers, remained above unity also after more than 10 years. 
The relative risk tended to be higher among patients without 
ulcer complications (SIR 2.6; 95% CI 1.5 to 4.3) compared with 
those with complicated disease. Trends with sex, age or 
calendar year at entry could not be interpreted because of 
small numbers. We found a borderline significant 30% excess 
risk of OSCC compared with the matching general Swedish 
population (n = 44, SIR 1.3, 95% CI 0.96 to 1.8). The excess was 
seemingly confined to follow-up years 2–10 and falling with 
increasing age at index hospitalisation; however, wide CIs 
precluded firm conclusions. 
Gastric ulcer 
During follow-up for an average of 7.2 years among 81 379 
unoperated patients with gastric ulcer, 18 cases of OAC were 
diagnosed from year two and onwards (SIR 1.1, 95% CI 0.6 to 
1.7; table 3). No conspicuous variation was observed in 
stratified analyses by follow-up duration, sex, complication 
history, calendar year and age at entry, but the observed 
number of cases in each stratum was small and the CIs were 
wide. In contrast, we observed a significant 80% increase in the 
relative risk of OSCC (n = 70, SIR 1.8, 95% CI 1.4 to 2.3) 
compared with the age, sex and calendar-period-matched 
general population. The excess was slightly more marked 
among men than women, and among younger than older 
patients, with a significant agewise trend (p,0.01; table 3). 
DISCUSSION 
This study was prompted by recent and relatively consistent 
reports of a strong inverse association between H pylori 
seropositivity and risk of OAC.8–10 13 The mechanisms under­
lying this apparent but enigmatic protection against OAC were 
first assumed to be H pylori-induced atrophic gastritis, hypo­
chlorhydria and reduction of acid reflux into the oesophagus, a 
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Table 1 Characteristics of patients hospitalised for peptic ulcer in Sweden, 1965–2003 
Duodenal ulcer Gastric ulcer Characteristics 
Number of patients 61,548 81,379 
Male (%) 64.5 52.6 
Age at index hospitalisation (%), years 
,40 12.1 6.2 
40–49 11.9 8.5 
50–59 16.2 14.3 
60–69 19.8 20.4 
70–79 24.0 28.9 
>80 16.0 21.7 
Mean 62.1 66.7 
Reason for index hospitalisation (%) 
Bleeding 49 47 
Perforation 9 9 
Other 42 44 
Total person–years of follow-up* 524 960 576 458 
Average follow-up time, years 9.1 7.2 
Mean age at diagnosis of cancer,* years 
Oesophageal adenocarcinoma 72.0 75.0 
Oesophageal squamous cell carcinoma 69.0 70.0 
*First year of follow-up was excluded. 
strong risk factor for OAC. A closer look at the association, 
however, revealed that indices of gastric atrophy, either in the 
form of low pepsinogen I levels10 or clinical pernicious 
anaemia17 were unrelated to risk of OAC. This information 
suggests that the presumed reduction of acid exposure in the 
oesophagus may not be critical to the H pylori-associated 
protection against OAC. Because duodenal ulcer could serve as 
a marker of antrum-predominant H pylori infection with 
hyperchlorhydria, and gastric ulcer could likewise be seen as 
a marker of H pylori infection, but with a more proximal 
distribution and a tendency rather towards atrophy and 
hypochlorhydria, the relation of these two types of ulcer to 
the risk of OAC and OSCC could potentially be informative. We 
hypothesised that patients with duodenal ulcer, who are almost 
invariably infected with H pylori, would have a low risk of OAC, 
OSCC,
and that patients with gastric ulcer would have a similarly 
reduced risk. Contrary to our expectation, however, the present 
study revealed a 70% excess risk for OAC among patients with 
duodenal ulcer, whereas the relative risk among patients with 
gastric ulcer was close to unity. Because previous studies 
suggested that isolated CagA seropositivity (a possible marker 
of a previous burned-out infection27) as well as clinical or 
serological indicators of atrophic gastritis may be risk factors for 
10 17 we further hypothesised that patients with gastric 
ulcer, but not those with duodenal ulcer, might have an 
increased risk for OSCC. The latter hypothesis was essentially 
confirmed. 
Strengths of our study include the large sample size and the 
cohort design with almost complete follow-up. However, like in 
most register-based studies, the lack of information about 
Table 2 Standardised incidence ratios (SIRs) and their 95% CIs for oesophageal cancer by 
histology among non-operated patients with duodenal ulcer, by follow-up duration, sex, 
presence of complications and calendar year of index hospitalisation* 
Adenocarcinoma Squamous cell carcinoma 
Number of 
cases SIR (95% CI) 
Number of 
cases SIR (95% CI) 
Overall 27 1.7 (1.1–2.5) 44 1.3 (0.96–1.8) 
Follow-up duration, years 
2–10 17 1.9 (1.1–3.1) 33 1.6 (1.1–2.2) 
11+ 10 1.5 (0.7–2.8) 11 0.9 (0.5–1.6) 
p for trend 0.15 0.01 
Sex 
Men 23 1.7 (1.1–2.5) 34 1.3 (0.9–1.8) 
Women 4 2.1 (0.6–5.5) 10 1.5 (0.7–2.7) 
Complicationt 
Yes 12 1.2 (0.6–2.1) 30 1.4 (0.95–2.0) 
No 15 2.6 (1.5–4.3) 14 1.2 (0.6–2.0) 
Calendar year of index hospitalisation 
1965–79 10 2.1 (1.0–3.8) 18 1.3 (0.8–2.1) 
1980–2003 17 1.6 (0.9–2.5) 26 1.3 (0.9–2.0) 
Age at entry 
,50 6 2.4 (0.9–5.1) 9 2.0 (0.9–3.8) 
50–69 15 1.9 (1.1–3.1) 25 1.4 (0.9–2.1) 
70– 6 1.2 (0.4–2.5) 10 0.9 (0.4–1.6) 
p for trend 0.09 ,0.001 
Calendar year of follow-up 
1965–94 13 2.3 (1.2–4.0) 25 1.2 (0.8–1.8) 
1995–2003 14 1.4 (0.8–2.3) 19 1.5 (0.9–2.3) 
*First year of follow-up was excluded. 
tIncluding bleeding and perforation. 
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Table 3 Standardised incidence ratios (SIRs) and their 95% CIs for oesophageal cancer by 
histology among unoperated patients with gastric ulcer, by follow-up duration, sex, presence of 
complications and calendar year of index hospitalisation* 
Adenocarcinoma Squamous cell carcinoma 
Number 
of cases SIR (95% CI) 
Number 
of cases SIR (95% CI) 
Overall 18 1.1 (0.6–1.7) 70 1.8 (1.4–2.3) 
Follow-up duration, years 
2–10 12 1.1 (0.6–2.0) 48 1.8 (1.3–2.4) 
11+ 6 1.0 (0.4–2.2) 22 1.9 (1.2–2.9) 
Sex 
Men 15 1.1 (0.6–1.9) 53 2.0 (1.5–2.6) 
Women 3 0.9 (0.2–2.7) 17 1.5 (0.8–2.3) 
Complicationt 
Yes 11 1.1 (0.6–2.0) 39 1.7 (1.2–2.3) 
No 7 1.1 (0.4–2.2) 31 2.1 (1.4–2.9) 
Calendar year of index hospitalisation 
1965–79 4 1.0 (0.3–2.4) 26 1.9 (1.2–2.8) 
1980–2003 14 1.1 (0.6–1.9) 44 1.8 (1.3–2.4) 
Age at entry 
,50 2 1.2 (0.1–4.2) 10 3.2 (1.5–5.8) 
50–69 10 1.2 (0.6–2.3) 43 2.2 (1.6–3.0) 
70– 6 0.9 (0.3–1.9) 17 1.1 (0.6–1.7) 
P for trend 0.49 ,0.01 
Calendar year of follow-up 
1965–94 5 0.8 (0.3–1.9) 38 1.6 (1.1–2.2) 
1995–2003 13 1.3 (0.7–2.1) 32 2.2 (1.5–3.1) 
*First year of follow-up was excluded 
tIncluding bleeding and perforation. 
OAC,
possible confounding factors is an important limitation. 
Smoking—linked to both duodenal ulcer and OAC—is such a 
factor that could have attenuated an H pylori-driven inverse 
association between these two diseases. However, the strength 
of the associations of smoking with both duodenal ulcer and 
OAC is comparably moderate and is unlikely to have shifted a 
70–80% protection, as judged from the direct studies on H pylori 
seroprevalence and OAC risk,8–10 13 to a 70% increased risk. The 
comparably weak link between smoking and unoperated 
duodenal ulcer in our cohort is demonstrated by the moderate 
association (SIR 1.6) with lung cancer risk (data not shown). 
Cyclooxygenase inhibitors such as aspirin or some other non-
steroidal anti-inflammatory drugs constitute other factors, 
which are tentatively associated with both peptic ulcer and 
28 29 and could thus be true confounders. However, because 
these drugs seem to protect against OAC, such confounding 
would tend to strengthen a true inverse association, not to 
cancel it. 
Until H pylori eradication became first-line treatment for 
peptic ulcer in the mid-1990s, H2-receptor antagonists and 
proton pump inhibitors were widely and generously used in 
these patients, particularly in those with duodenal ulcer. 
Although we lack information about medications in our register 
data, it seems reasonable to assume that aggressive treatment, 
including long-term maintenance therapy, was common in our 
cohorts, consisting of in-hospital patients with a high pre­
valence of complications. It is yet to be established if acid 
inhibition protects against OAC, but because of the apparent 
key role of gastro-oesophageal reflux in OAC aetiology, such 
treatment is more likely to reduce the risk than to increase it. 
Therefore, it is inconceivable that the widespread use of H2­
receptor antagonists or proton pump inhibitors would explain 
the increased OAC risk among duodenal ulcer patients. If 
anything, such treatment might have led to some under­
estimation of the duodenal ulcer-related excess of OAC. 
A second limitation is the lack of information about factual 
H pylori status. Although this weakness may seem less 
important among our almost invariably infected duodenal 
ulcer patients, a non-negligible proportion of our unexposed 
comparison group—the age, sex and calendar period-matched 
general Swedish population—carried antibodies to H pylori. 
Hence, whereas studies with individual data on H pylori status 
compare exposed groups, in which almost 100% are truly 
infected, with unexposed groups containing close to 0% 
infected, the corresponding percentages in our study are likely 
to be 90% versus 50–70%. This will attenuate any measure of 
association, but it will not reverse them. 
In the analysis of gastric ulcer, the combination of 
confounding by smoking and attenuation due to ‘‘misclassifi­
cation’’ of the H pylori status among the supposedly exposed 
ulcer patients (but only approximately 80% were infected) and 
the purportedly unexposed comparison population (but with a 
mean age of 66.7 years at entry probably close to 70% were 
infected) could conceivably have removed a substantial under­
lying inverse association between H pylori and OAC. Therefore, 
the absence of association should not be overinterpreted. A 
similar caveat must be highlighted for the moderately strong 
positive association between gastric ulcer and OSCC, which 
could potentially be explained by confounding by smoking, a 
strong risk factor for OSCC. The differential associations for 
gastric ulcer and duodenal ulcer, however, somewhat disagree 
with such confounding as the sole explanation. 
Although recent research10 has challenged the old hypothesis 
that H pylori protects against OAC by atrophic gastritis and 
hypoacidity, it appears that our present findings among 
patients with duodenal and gastric ulcers are, again, more in 
line with the original explanation. The oesophageal mucosa in 
individuals with duodenal ulcer is, on average, more exposed to 
gastric acid than that in healthy individuals,30 whereas it is 
likely to be less exposed in patients with gastric ulcer, linked to 
corpus gastritis and hypoacidity. According to the old hypoa­
cidity hypothesis, gastric ulcer patients, and those with 
manifest atrophic gastritis, should be the ones most protected 
against OAC. As discussed above, the H pylori-associated 
protection may not be faithfully reflected in the comparison 
with the general population, and what remains of the effect 
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might have been cancelled by confounding from smoking. An 
alternative but admittedly speculative explanation is that the 
non-surgical treatment offered to these patients in some way 
modifies the inverse H pylori–OAC relation. 
With due reservations, our finding of a positive association 
between gastric ulcer and risk of OSCC adds some further 
support for the hypothesis that the intragastric environment 
fostered by corpus atrophy may play a role in OSCC 
aetiology.10 31 In the atrophic, hypoacidic stomach, microorgan­
isms other than H pylori may thrive and generate intragastric 
nitrosamines.32 N-nitrosamines are suspected as a key risk 
factor for OSCC.33 Such tumours can be induced by N-nitroso 
compounds in animal models34–36 and endogenous nitrosamines 
that can reach the oesophageal mucosa through one or more 
unknown ways (reflux or through submucosal veins) seem to 
play a central role.37 
In conclusion, this study suggests that the repeatedly 
confirmed strong inverse relation between H pylori seropositiv­
ity and risk of OAC does not pertain to all infections. It appears 
as if the pattern of gastric colonisation and/or the clinical 
consequences in the stomach plays an important role. 
. . . . . . . . . . . . . . . . . . . . . . . 
  
Authors’ affiliations 
S Bahmanyar, K Zendehdel, O Nyre´n, W Ye, Department of Medical 
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 
S Bahmanyar, Faculty of Medicine, Golestan University of Medical 
Sciences, Gorgan, Iran 
K Zendehdel, Cancer Institute Research Centre, Tehran University of 
Medical Sciences, Tehran, Iran 
Competing interests: None. 
Part of the contents was presented at the 6th International Gastric Cancer 
Congress, Yokohama, Japan, 2005 
REFERENCES 
1 Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global 
picture. Eur J Cancer 2001;37(Suppl 8):4–66. 
2 Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. 
Semin Oncol 2004;31:450–64. 
3	 Younes M, Henson DE, Ertan A, et al. Incidence and survival trends of
 
esophageal carcinoma in the United States: racial and gender differences by
 
histological type. Scand J Gastroenterol 2002;37:1359–65.
 
4	 Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major 
histologic types of esophageal carcinomas in selected countries, 1973–1995. 
Int J Cancer 2002;99:860–8. 
5	 Nguyen AM, Luke CG, Roder D. Comparative epidemiological characteristics of 
oesophageal adenocarcinoma and other cancers of the oesophagus and gastric 
cardia. Asian Pac J Cancer Prev 2003;4:225–31. 
6	 van Blankenstein M, Looman CW, Hop WC, et al. The incidence of
 
adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett’s
 
esophagus makes a difference. Am J Gastroenterol 2005;100:766–74.
 
7	 Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains 
and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 
2003;103:815–21. 
8	 Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains 
of Helicobacter pylori infection and risk of esophageal and gastric cardia 
adenocarcinoma. Cancer Res 1998;58:588–90. 
9 de Martel C, Llosa AE, Farr SM, et al. Helicobacter pylori infection and the risk of
 
development of esophageal adenocarcinoma. J Infect Dis 2005;191:761–7.
 
10 Ye W, Held M, Lagergren J, Engstrand L, et al. Helicobacter pylori infection and
 
gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the
 
esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 
2004;96:388–96. 
11	 Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and 
humans: implications for health and disease. J Infect Dis 1999;179:1523–30. 
12	 Clark GW. Effect of Helicobacter pylori infection in Barrett’s esophagus and the 
genesis of esophageal adenocarcinoma. World J Surg 2003;27:994–8. 
13	 Henrik Siman J, Forsgren A, Berglund G, et al. Helicobacter pylori infection is 
associated with a decreased risk of developing oesophageal neoplasms. 
Helicobacter 2001;6:310–6. 
14	 Sharma P, Vakil N. Helicobacter pylori and reflux disease. Aliment Pharmacol 
Ther 2003;17:297–305. 
15	 Warburton-Timms VJ, Charlett A, Valori RM, et al. The significance of cagA(+) 
Helicobacter pylori in reflux oesophagitis. Gut 2001;49:341–6. 
16	 Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux 
disease: the bug may not be all bad. Am J Gastroenterol 1998;93:1800–2. 
17	 Ye W, Nyren O. Risk of cancers of the oesophagus and stomach by histology or 
subsite in patients hospitalised for pernicious anaemia. Gut 2003;52:938–41. 
18	 Kupcinskas L, Jonaitis L, Kiudelis G. A 1 year follow-up study of the 
consequences of Helicobacter pylori eradication in duodenal ulcer patients: 
unchanged frequency of erosive oesophagitis and decreased prevalence of non-
erosive gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 
2004;16:369–74. 
19	 Ishiki K, Mizuno M, Take S, et al. Helicobacter pylori eradication improves pre­
existing reflux esophagitis in patients with duodenal ulcer disease. Clin 
Gastroenterol Hepatol 2004;2:474–9. 
20	 IARC. Schistosomes, liver flukes and Helicobacter pylori. Lyon, France: IARC, 
1994, IARC monographs on the evaluation of carcinogenic risks to humans.. 
21	 Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002;360:933–41. 
22	 Seymour NE, Andersen DK. Surgery for peptic ulcer disease and postastrectomy 
sydromes. In: Yamada T, eds. Gastroenterology.4th edn. Philadelphia: Lippincott 
Williams & Wilkins, 2003. 
23	 Cohen H. Peptic ulcer and Helicobacter pylori. Gastroenterol Clin North Am 
2000;29:775–89. 
24	 ISCD. International statistical classification of diseases, injuries, and causes of 
death, 1955 rev edn. Stockholm, Sweden: Kungliga Medicinalstyrelsen, 1965. 
25	 Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-
notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 
1984;23:305–13. 
26	 Breslow NE, Day NE. Statistical methods in cancer research. Volume II. The 
design and analysis of cohort studies. IARC Sci Publ 1987;82:1–406. 
27	 Ye W, Held M, Enroth H, et al. Histology and culture results among subjects with 
antibodies to CagA but no evidence of Helicobacter pylori infection with IgG 
ELISA. Scand J Gastroenterol 2005;40:312–8. 
28	 Gammon MD, Terry MB, Arber N, et al. Nonsteroidal anti-inflammatory drug 
use associated with reduced incidence of adenocarcinomas of the esophagus 
and gastric cardia that overexpress cyclin D1: a population-based study. Cancer 
Epidemiol Biomarkers Prev 2004;13:34–9. 
29	 Bardou M, Barkun AN, Ghosn J, et al. Effect of chronic intake of NSAIDs and 
cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin 
Gastroenterol Hepatol 2004;2:880–7. 
30	 Wallin L. Gastro-oesophageal function in duodenal ulcer patients. 
Scand J Gastroenterol 1980;15:145–50. 
31	 Limburg PJ, Dawsey SM, Qiao Y, et al. Helicobacter pylori seropositivity and 
esophageal squamous cancer risk in Lianxian, China. Gastroenterology 
2000;118:A724. 
32	 Axon ATR, Dixon MF, Sue-Line HM. Gastric cancer. In: Scheppach W, 
Bresalier RS, Tytgat GN, eds. Gastroitestinal and liver tumors. Berlin Heidelberg: 
Springer-Verlag, 2004. 
33	 Craddock VM. Aetiology of oesophageal cancer: some operative factors. 
Eur J Cancer Prev 1992;1:89–103. 
34	 Mirvish SS, Nickols J, Weisenburger DD, et al. Carcinogenicity tests of methyl-n­
amylnitrosamine (MNAN) administered to newborn and adult rats and hamsters 
and adult mice and of 2-oxo-MNAN administered to adult rats. Cancer Lett 
1996;107:171–7. 
35	 Reznik G, Mohr U, Kmoch N. Carcinogenic effects of different nitroso­
compounds in Chinese hamsters. I. Dimethylnitrosamine and N­
diethylnitrosamine. Br J Cancer 1976;33:411–8. 
36	 Ivankovic S, Seibel J, Komitowski D, et al. Caffeine-derived N-nitroso 
compounds. V. Carcinogenicity of mononitrosocaffeidine and dinitrosocaffeidine 
in bd-ix rats. Carcinogenesis 1998;19:933–7. 
37	 Wu Y, Chen J, Ohshima H, et al. Geographic association between urinary 
excretion of N-nitroso compounds and oesophageal cancer mortality in China. 
Int J Cancer 1993;54:713–9. 
www.gutjnl.com 
